-0.62%
1.70%
-16.11%
-7.08%
-22.93%
1.81%
8.37%
AI Spotlight on FOLD
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development.
The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline.Amicus Therapeutics, Inc.was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Market Data
| Last Price | 9.58 |
| Change Percentage | -0.62% |
| Open | 9.62 |
| Previous Close | 9.64 |
| Market Cap ( Millions) | 2863 |
| Volume | 1742711 |
| Year High | 14.03 |
| Year Low | 8.79 |
| M A 50 | 9.65 |
| M A 200 | 10.38 |
Financial Ratios
| FCF Yield | -1.10% |
| Dividend Yield | 0.00% |
| ROE | -69.54% |
| Debt / Equity | 248.66% |
| Net Debt / EBIDTA | -2294.85% |
| Price To Book | 16.32 |
| Price Earnings Ratio | -27.88 |
| Price To FCF | -90.84 |
| Price To sales | 5.8 |
| EV / EBITDA | -334.27 |
News
- Jan -23 - NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases
- Jan -13 - NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined
- Jan -13 - 3 Oversold Biotech Names
- Jan -13 - Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
- Jan -12 - Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
- Jan -02 - Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -27 - Amicus Therapeutics: Cheap Heading Into 2025
- Dec -23 - NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It
- Dec -23 - HALO or FOLD: Which Is the Better Value Stock Right Now?
- Dec -18 - NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act
- Dec -13 - Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension
- Dec -13 - Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
- Dec -05 - HALO vs. FOLD: Which Stock Is the Better Value Option?
- Dec -03 - NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial
- Nov -19 - HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
- Nov -13 - NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights
- Nov -07 - Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
- Nov -07 - Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
- Nov -06 - Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
- Nov -06 - Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Advanced Therapies
Expected Growth : 11.3 %
What the company do ?
Advanced Therapies from Amicus Therapeutics, Inc. are innovative, one-time treatments for rare genetic diseases, using gene therapy, gene editing, and gene modulation.
Why we expect these perspectives ?
Amicus Therapeutics' Advanced Therapies segment growth of 11.3% is driven by increasing adoption of its gene therapies, particularly AT-GAA for Pompe disease, and strong demand for its Fabry disease treatment, Galafold. Additionally, the company's expanding commercial presence, strategic partnerships, and ongoing R&D investments in novel gene therapies contribute to its growth momentum.
Amicus Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Galafold | Galafold is a pharmacological chaperone therapy for the treatment of Fabry disease, a rare genetic disorder caused by the deficiency of the alpha-galactosidase A enzyme. |
| AT-GAA | AT-GAA is a gene therapy for the treatment of Pompe disease, a rare genetic disorder caused by the deficiency of the acid alpha-glucosidase enzyme. |
| CLN6 | CLN6 is a gene therapy for the treatment of Batten disease, a rare genetic disorder caused by the deficiency of the CLN6 protein. |
| ATB200/AT220 | ATB200/AT220 is a pharmacological chaperone therapy for the treatment of Pompe disease, a rare genetic disorder caused by the deficiency of the acid alpha-glucosidase enzyme. |
Amicus Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Amicus Therapeutics, Inc. is medium due to the presence of alternative treatments and therapies for rare genetic diseases. While there are some substitutes available, they may not be as effective or convenient as Amicus' products.
Bargaining Power Of Customers
The bargaining power of customers for Amicus Therapeutics, Inc. is low due to the specialized nature of its products and the lack of alternative treatments for rare genetic diseases. Patients and healthcare providers have limited bargaining power.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Amicus Therapeutics, Inc. is medium due to the presence of multiple suppliers for raw materials and manufacturing services. However, the company's dependence on a few key suppliers for certain components may give them some bargaining power.
Threat Of New Entrants
The threat of new entrants for Amicus Therapeutics, Inc. is low due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development, manufacturing, and regulatory approvals.
Intensity Of Rivalry
The intensity of rivalry for Amicus Therapeutics, Inc. is high due to the presence of several established competitors in the biotechnology industry, as well as the potential for new entrants. The company operates in a highly competitive market with many players vying for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 71.21% |
| Debt Cost | 7.92% |
| Equity Weight | 28.79% |
| Equity Cost | 7.92% |
| WACC | 7.92% |
| Leverage | 247.34% |
Amicus Therapeutics, Inc. : Quality Control
Amicus Therapeutics, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| CLDX | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with … |
| RYTM | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| PTCT | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
Denali Therapeutics
A-Score
1-Year Total Return ->
🥉
Amicus Therapeutics
A-Score
1-Year Total Return ->
4
Rhythm Pharma
A-Score
1-Year Total Return ->
5
Celldex Therapeutics
A-Score
1-Year Total Return ->
6
